Evaluation of standard diagnostic rapid test kits for malaria diagnosis among HIV patients in Kano, Nigeria

Background: Malaria diagnosis among HIV-positive patients is uncommon in Nigeria despite the high burden of both diseases.

Objectives: We evaluated the performance of a malaria rapid diagnostic test (MRDT) against blood smear microscopy (BSM) among HIV-positive patients in relation to anti-retroviral treatment (ART) status, CD4+ count, fever, cotrimoxazole prophylaxis and malaria density count.

Method: A cross-sectional study involving 1521 consenting randomly selected HIV-positive adults attending two ART clinics in Kano, Nigeria, between June 2015 and May 2016. Venous blood samples were collected for testing with MRDT, BSM, and CD4+ T cells count by cytometry. Biodata and other clinical details were extracted from patient folders into an Excel file, cleaned, validated, and exported for analysis into SPSS version 23.0. Sensitivity, specificity, predictive values of MRDT were compared with BSM with a 95% confidence interval.

Results: Malaria parasites were detected in 25.4% of enrollees by BSM and 16.4% by MRDT. Overall sensitivity of MRDT was 58% and specificity was 97%. Cotrimoxazole prophylaxis and fever status did not affect MRDT sensitivity and specificity. Unexpectedly, the specificity was highest at parasite density count of less than 500 cells/µL at CD4+ count over 500 cells/µL. The sensitivity was higher (62.4%) compared to patients with less than 500 cells/µL. In the non-ART group sensitivity was higher (65%) compared to those on ART (56%) but the specificity was similar. All differences were significant for all variables (p < 0.05).

Conclusion: Although the MRDT specificity was good, the sensitivity was poor, requiring further evaluation for use in malaria diagnosis among HIV-malaria co-infected persons in these settings.

Introduction

Malaria remains a major public health problem in Nigeria with 97% of the population at risk. In 2016 Nigeria had about 57.3 million cases of malaria with over 112 000 deaths reported. Although malaria prevalence in Nigeria varied between states, a 60.6% prevalence has been reported in a population-based study across five local government areas of Kano State. HIV prevalence among adults in Nigeria was about 2.9% with about 3.2 million persons living with HIV in 2016. The greatest burden of disease due to both HIV and malaria (predominantly Plasmodium falciparum) occurs commonly in sub-Saharan Africa and the rates of co-infection make interaction between both diseases a global health focus.

A key factor for effective management of malaria is early and accurate diagnosis. The global impact of malaria has prompted an increase in the development of diagnostic strategies. The updated World Health Organization (WHO) recommendations indicate that all suspected cases of malaria must be confirmed with a laboratory diagnostic test before treatment. This enables differentiation of malarial and non-malarial fevers, to prevent unnecessary use of antimalarial drugs. This is very crucial among HIV-positive patients, where febrile illnesses other than malaria are common. Opportunistic infections and other febrile illnesses mimic malaria in HIV patients.

Although microscopy is the current gold standard for the diagnosis of malaria, it is time consuming and labour intensive. In many malaria-endemic areas like Nigeria, it is difficult to maintain the required technical skills, equipment and infrastructure particularly in rural areas, where...
the disease is more prevalent. Hence, the use of rapid diagnostic tests (RDT) in such endemic areas is recommended.\textsuperscript{16,17} Furthermore, part of the national malaria control strategy plan for 2014 to 2020, with a vision of having a malaria-free Nigeria, is to test all care-seeking persons suspected of suffering from malaria using RDT or microscopy.\textsuperscript{1}

Data from reviewed literature showed that very few studies have evaluated the validity of RDT for malaria diagnosis in the general population in Nigeria.\textsuperscript{14,15,16} Thus far, only one study has evaluated the performance of a malaria RDT (MRDT) among 387 HIV-positive persons in Nigeria.\textsuperscript{19} Overall MRDT sensitivity, specificity, positive and negative predictive value have not yet been properly evaluated especially among HIV-positive individuals.\textsuperscript{20,21}

The objective of the study was to evaluate the performance of a commercially available MRDT (based on \textit{P. falciparum} histidine-rich protein type-2 and \textit{Plasmodium} lactate dehydrogenase), the Standard Diagnostics (SD) Bioline MRDT, compared to the gold standard, microscopy, in the diagnosis of malaria among HIV-positive participants with respect to malaria parasite density, CD4+ T cells count, cotrimoxazole prophylaxis use, anti-retroviral treatment (ART) status and occurrence of fever. The choice of SD Bioline was on the premise that this rapid test kit is the most commonly used MRDT for routine malaria diagnosis in Kano State.

**Materials and methods**

**Ethical considerations**

The protocol was reviewed by Kano State Hospitals Management Board local ethical committee and written approval was given (study approval number: HMB/GEN/488/1 of 17/04/2015). Participant consent was obtained from all respondents.

**Study setting and population**

This was a cross-sectional study carried out from June 2015 to May 2016 at two health facilities in Kano City, Nigeria, a malaria endemic area.\textsuperscript{3} The facilities are Infectious Diseases Hospital Kano (IDH) and Murtala Mohammed Specialist Hospital Kano.

The population of interest in this study were HIV-positive adult participants who routinely visit the two health facilities to access ART services. They consisted of male and female (non-pregnant) patients (on ART and non-ART) aged 18 years and older enrolled in an ART programme who had not been on an antimalarial drug in the past 14 days and who willfully consented to participate in the study.

**Data collection and sampling technique**

A total of 1521 consenting participants were randomly selected and blood specimens were collected and analysed for the presence of malaria parasite using both RDT and microscopy techniques and density of malaria parasites was determined. Additionally, relevant socio-demographic and clinical data including clients’ code, age, gender, use of cotrimoxazole prophylaxis, ART status (receiving or not receiving treatment), and episodes of fever were retrieved from both patients’ folders and Lafiya Management Information System (LAMIS\textsuperscript{®}) software with the support of trained data entry clerks. We ensured data confidentiality through participant coding and restricting access to the data to only research team members.

**Laboratory analysis (rapid diagnostic test, blood microscopy and parasite density determination)**

From 1521 consenting HIV-positive participants, 4 mL venous blood sample was aseptically collected using sterile vacutainer needle and holder into an ethylenediaminetetraacetic acid (EDTA) anticoagulant tube. The blood samples were mixed properly to avoid clotting before laboratory investigations.

We used the MRDT kit (Code 05FK30) as described by the manufacturers (Standard Diagnostics Bioline Korea, 2013). For microscopy slide method, both thin and thick smear slides were prepared and examined. The microscopy procedure adopted was described by WHO.\textsuperscript{22} To ensure the quality of testing, MRTD and microscopy were performed by independent laboratory personnel and MRTD results were blinded to microscopists. All MRTD kits were stored according to manufacturer recommendation and used before the expiry date. The two microscopists responsible for slide examinations in both facilities have attended WHO training on malaria microscopy. Additionally, 10% of the slides were randomly selected for re-testing. About 2% of the results were discordant between the first and second readers and were subjected to further evaluation by a third reader before a final decision was made.

Malaria parasite density for each positive smear was calculated using individual white blood cell count according to this formula:

\[
\text{malaria parasite count} = \frac{\text{Number of parasite count} \times \text{patient actual white blood cell count/μL}}{\text{Number of white blood cell count 200 or 500}}
\]

**Data processing and analysis**

Data were reviewed, cleaned and validated in a Microsoft 2013 Excel file (Microsoft Corp., Redmond, Washington, United States) and analysed using Statistical Package for Social Scientists (SPSS version 23.0; IBM, Armonk, New York, United States). The sensitivity, specificity, positive predictive value and negative predictive value of MRDT were estimated against blood smear microscopy (BSM), the gold standard, at 95% confidence interval in relation to (1) malaria parasite density count, (2) fever (presence or absence), (3) CD4+ T cells count, (4) co-trimoxazole prophylaxis use, and (5) ART status.
status (currently on ART or not taking ART). In addition, differences in performance of MRDT against BSM were analysed (overall and for sub-groups of the five variables mentioned above) based on level of ‘equality of marginal positives’ in disease classification between the two using McNemar tests and significance level was set at \( p < 0.05 \).

**Results**

**Study population**

This study included a total of 1521 HIV-positive participants consisting of 1074 (70.6%) women and 447 (29.4%) men. The mean age was 37.20 with a standard deviation (SD) of 10.41 years.

Data on clinical information showed that the majority (84.7%) were on ART. An almost equal proportion of the participants \((n = 772, 50.8\%)\) were on daily dose co-trimoxazole prophylaxis for prevention against opportunistic infection including malaria parasite infection while 749 (49.2%) were not on co-trimoxazole prophylaxis. About (7%) complained of fever. The mean current CD4+T cells count of the participants was 401.35 cells/µL ± 239.24 cells/µL, and ranged from 6 cells/µL to 1736 cells/µL. The majority \((n = 1038, 68.2\%)\) of the respondents had a CD4+T cells count lower than 500 cells/µL, while 31.8\%(n = 483) had CD4+ T cell counts of 500 cells/µL or higher. The mean malaria parasite density was 265 cells/µL ± 31.8 (SD) cells/µL with a range of 20 cells/µL to 2500 cells/µL. A majority (87.8\%) had malaria parasite density less than 500 cells/µL, while the rest (12.2\%) had parasite density 500 cells/µL or higher.

**Prevalence of malaria parasite among HIV-positive patients based on microscopy versus malaria rapid diagnosis test**

The prevalence of malaria was 25.4% with BSM technique (gold standard method) and only 16.4% with MRDT. It is worth nothing that participants were recruited at routine ART follow-up visits, with or without symptoms of malaria. Almost all (99.2\%) malaria infections were *Plasmodium falciparum* species while dual infection of *Plasmodium falciparum* and *Plasmodium vivax* species occurred in only three (0.8\%) participants (Table 1). The overall sensitivity of the MRDT method was 58\% and specificity 97\%. The positive predictive value was 89% and the negative predictive value was 87\% (Table 2). A 2.5\% (28/1135) false positive result and 27.6\% (55/200) false negative result were observed.

Overall, there was significant difference in MRDT performance compared to BSM \((p < 0.001)\), with the MRDT demonstrating a ‘fair’ performance and discriminatory capacity of 0.775 (Area under the curve = 0.775, 95\% CI: 0.743–0.804) of the studied population.

**Performance of malaria rapid diagnostic test in comparison with standard microscopy**

**Different malaria parasite densities**

The MRDT showed a sensitivity of about 72\% among HIV-positive patients with malaria density count between 0 and 499 cells/µL and greater than 1000 cells/µL. Unexpectedly, a low sensitivity of about 34\% was observed when density was between 500 and 999 cells/µL (Table 3).

MRDT performance was significantly different from BSM findings, regardless of malaria parasite density count of participants \((p < 0.005)\).

**Presence or absence of fever**

The MRDT showed slightly lower but similar sensitivity in cases with and without fever, but similar specificity for both groups of participants. However, positive predictive value was higher (95.6\%) among clients that complained of fever compared to those without (88.1\%) fever (Table 3). In those with or without fever, MRDT performance was significantly lower compared to BSM findings \((p < 0.0)\).

**Co-trimoxazole prophylaxis**

MRDT performed similarly in sensitivity and specificity in both groups, although higher positive predictive value was observed among participants who were not on co-trimoxazole (Table 3). Regardless of participant’s co-trimoxazole status, the performance of MRDT was significantly lower in

**TABLE 1: Prevalence of malaria parasite among HIV-positive patients determined by malaria rapid diagnosis test and standard blood smear microscopy.**

| Variables               | Malaria positive \( n \) | Percentage | Malaria negative \( n \) | Percentage |
|-------------------------|--------------------------|------------|--------------------------|------------|
| RDT MP parasite species Pf&Pv | 250                      | 16.4\%     | 1271                     | 83.7\%     |
| Prevalence of malaria & HIV | 386                      | 25.4\%     | 1135                     | 74.6\%     |
| BSM MP parasite species Pf | 383                      | 25.2\%     | -                        | -          |
| BSM MP parasite species Pf&Pv | 3                       | 0.2\%      | -                        | -          |
| Overall Pf species prevalence | 383                    | 99.2\%     | -                        | -          |
| Mixed infection prevalence | 3                      | 0.8\%      | -                        | -          |

BSM, blood smear microscopy significant difference; MP, Malaria parasites; \( n \), number; Pf, Plasmodium falciparum; Pv, Plasmodium vivax; HIV, human immunodeficiency virus; RDT, rapid diagnostic test.

| RDT result | Standard BSM |
|------------|--------------|
| Positive  | Negative    | Sensitivity | Specificity | PPV   | NPV   | LR +ve | LR -ve | McNemar test \( p \) value |
| Positive  | 222          | 28          | 57.5 (52.41–62.50) | 97.3 (96.45–98.35) | 88.8 (84.48–92.03) | 87.1 (85.73–88.35) | 21.29 | 0.44 | <0.001 |
| Negative  | 164          | 1107        | -           | -        | -        | -      | -      | -      |
| Total     | 386          | 1135        | -           | -        | -        | -      | -      | -      |

HIV, human immunodeficiency virus; BSM, blood smear microscopy; LR, likelihood ratio; NPV, negative predictive value; PPV, predictive positive value; RDT, rapid diagnostic test.
sensitivity and specificity compared to BSM findings ($p < 0.001$) in both groups.

**Current CD4+T cells count/µL**

MRDT revealed higher (sensitivity 62%, specificity 99%, positive predictive value 91% and negative predictive value 91%) diagnostic accuracy among participants with CD4+T cells count greater than 500 cells/µL. This was lower (sensitivity 56%, specificity 97%, positive predictive value 88% and negative predictive value 85%) among participants with CD4+T cells count under 500 cells/µL (Table 3). The observed differences in performance were statistically significant ($p < 0.001$).

**Anti-retroviral treatment status**

The MRDT revealed a higher (65%) sensitivity among HIV participants who were not on ART compared (56%) to those on ART. A similar pattern of higher positive predictive value (88%) was observed among the non-ART group compared to 87% among the ART group (Table 3). For both groups of participants (ART vs non-ART), the observed differences in performance of MRDT were significantly

| TABLE 3: Performance of malaria rapid diagnostic test in comparison with standard blood smear microscopy at different malaria parasite density, fever status, cotrimoxazole prophylaxis, CD4+ count and ART status |
|------------------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| RDT result                   | Standard BSM                 |                  |                  |                  |                  |                  |                  |
|                              | Positive | Negative | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | McNemar test ($p$) |
| Parasite density 0–499 µL    |          |          | 72.5 (65.76–78.56) | 97.5 (96.45–98.35) | 83.8 (78.06–88.29) | 95.3 (94.14–96.18) | 0.004 |
| Positive                     | 145      | 28       |                  |                  |                  |                  |                  |
| Negative                     | 55       | 1107     |                  |                  |                  |                  |                  |
| Total                        | 200      | 1135     |                  |                  |                  |                  |                  |
| Parasite density 500–999 µL  |          |          | 33.8             | NA               | 100.0           | NA               | < 0.001 |
| Positive                     | 50       | 0        |                  |                  |                  |                  |                  |
| Negative                     | 98       | 0        |                  |                  |                  |                  |                  |
| Total                        | 148      | 0        |                  |                  |                  |                  |                  |
| Parasite density ≥ 1000 µL   |          |          | 71.1             | NA               | 100.0           | NA               | < 0.001 |
| Positive                     | 27       | 0        |                  |                  |                  |                  |                  |
| Negative                     | 11       | 0        |                  |                  |                  |                  |                  |
| Total                        | 38       | 0        |                  |                  |                  |                  |                  |
| Fever                        |          |          |                  |                  |                  |                  |                  |
| Positive                     | 23       | 1        | 54.8 (39.72–69.84) | 98.4 (95.31–99.99) | 95.8 (87.83–99.97) | 76.5 (67.34–85.81) | < 0.001 |
| Negative                     | 19       | 62       |                  |                  |                  |                  |                  |
| Total                        | 42       | 63       |                  |                  |                  |                  |                  |
| No Fever                     |          |          |                  |                  |                  |                  |                  |
| Positive                     | 199      | 27       | 73.8 (52.63–63.14) | 96.53–98.42) | 81.3 (80.82–92.32) | 87.8 (86.04–89.72) | < 0.001 |
| Negative                     | 145      | 1045     |                  |                  |                  |                  |                  |
| Total                        | 344      | 1135     |                  |                  |                  |                  |                  |
| On CTX                       |          |          |                  |                  |                  |                  |                  |
| Positive                     | 97       | 18       | 57.7 (49.89–65.31) | 97.0 (95.33–98.22) | 84.3 (77.05–89.64) | 89.2 (87.36–90.79) | < 0.001 |
| Negative                     | 71       | 56       |                  |                  |                  |                  |                  |
| Total                        | 168      | 604      |                  |                  |                  |                  |                  |
| Not on CTX                   |          |          |                  |                  |                  |                  |                  |
| Positive                     | 125      | 10       | 57.3 (50.48–63.99) | 98.1 (95.66–99.09) | 92.6 (87.00–95.89) | 84.9 (82.76–86.73) | < 0.001 |
| Negative                     | 93       | 521      |                  |                  |                  |                  |                  |
| Total                        | 218      | 531      |                  |                  |                  |                  |                  |
| CD4+ count ≤ 500 cells/µL    |          |          |                  |                  |                  |                  |                  |
| Positive                     | 164      | 22       | 56.0 (50.08–61.74) | 97.0 (95.56–98.14) | 88.2 (82.99–91.93) | 84.9 (83.12–86.45) | < 0.001 |
| Negative                     | 129      | 723      |                  |                  |                  |                  |                  |
| Total                        | 293      | 745      |                  |                  |                  |                  |                  |
| CD4+ count > 500 cells/µL    |          |          |                  |                  |                  |                  |                  |
| Positive                     | 58       | 6        | 62.4 (51.72–72.21) | 98.5 (96.68–99.43) | 90.6 (81.14–95.60) | 91.6 (89.41–93.45) | < 0.001 |
| Negative                     | 35       | 384      |                  |                  |                  |                  |                  |
| Total                        | 93       | 419      |                  |                  |                  |                  |                  |
| On ART                       |          |          |                  |                  |                  |                  |                  |
| Positive                     | 178      | 27       | 56.0 (50.33–61.51) | 97.2 (95.98–98.16) | 86.8 (81.78–90.64) | 87.1 (85.61–88.41) | < 0.001 |
| Negative                     | 140      | 943      |                  |                  |                  |                  |                  |
| Total                        | 318      | 970      |                  |                  |                  |                  |                  |
| Non-ART                      |          |          |                  |                  |                  |                  |                  |
| Positive                     | 44       | 1        | 64.7 (52.17–75.92) | 99.4 (96.67–99.98) | 97.8 (86.08–98.68) | 87.2 (83.20–90.41) | < 0.001 |
| Negative                     | 24       | 164      |                  |                  |                  |                  |                  |
| Total                        | 68       | 165      |                  |                  |                  |                  |                  |

BSM, blood smear microscopy; CI, confidence interval; CTX, cotrimoxazole; RDT, rapid diagnostic test; ART, antiretroviral therapy; NA, Not available; LR, likelihood ratio; NPV, negative predictive value; PPV, predictive positive value.
lower in sensitivity compared to BSM findings among the non-ART group ($p < 0.001$).

**Discussion**

We detected malaria parasites in 25.4% of participants by BSM and 16.4% by MRDT. Overall sensitivity of MRDT was 58% and specificity was 97%. The sensitivity and specificity were similar irrespective of co-trimoxazole and fever status. At malaria parasite density count of under 500 cells/µL, sensitivity was 73% and between 500 and 999 cells/µL, sensitivity was 34%. At CD4+ T cell count over 500 cells/µL the sensitivity was higher (62.4%) compared to 56% at under 500 cells/µL. In the non-ART group sensitivity was higher (65%) compared to those on ART (56%) but the specificity was similar.

Although blood smear microscopy still remains the gold standard for malaria diagnosis, several limitations ranging from infrastructure and equipment to competence still exist in endemic areas like Nigeria. These justify the need for an alternate method like MRDT. Since WHO recommended the use of MRDT, several test kits have flooded the market, hence the need for constant field validation to verify manufacturers’ claims. This is critical, particularly among HIV-positive patients in whom other febrile illnesses and infections mimic malaria.

The prevalence of malaria in HIV-positive patients in this study was 25.4% based on microscopy compared to 16.4% based on MRDT method. This was similar to a Tanzanian study reporting a malaria prevalence of 23.8% using microscopy method among HIV-positive patients compared to 17.5% with MRTD. However, our findings varied from a similar study in Lagos, Nigeria, involving a smaller sample size of 387 HIV patients where a malaria prevalence of about 19% was reported for both BSM and MRDT of another brand. Another study in Burkina Faso among 114 HIV-positive patients showed a malaria prevalence of about 45% for MRDT and 42% for BSM. It is worth noting that in this study, participants were recruited at routine follow-up visits, regardless of suspicion of malaria unlike the other studies comparing performance of BSM and MRDT in HIV-positive patients suspected of suffering from or having symptoms of malaria. For example, the Tanzania and Burkina Faso studies looked at HIV-positive children suspected of malaria, while those from Lagos, Uganda, and Malawi looked at adults with HIV attending outpatient clinics suspected of having malaria. Thus, the direct comparison of proportions positive for malaria in our studies with the others must be considered with caution.

MRDT overall sensitivity and specificity reported in this study was similar to a 55.4% sensitivity reported in Lagos, Nigeria, but varied in specificity (90.3%). Contrary to our results, a 100% sensitivity and similar specificity of about 95.4% was documented in a Burkina Faso study among HIV-positive participants. Other studies on MRDT performance among HIV-positive population in Malawi and different studies in Uganda have shown higher sensitivity of over 94%. In these studies, the specificities averaged over 97% like in ours except for the Malawi study that reported about 51% specificity.

The 2.5% false positive results observed with the use of MRDT may be an indicator of residual antigenemia. The average time that histidine rich protein-2 (PfHPR2) remains positive after resolution of parasitaemia is about 2 weeks, although it has been shown that the protein can take over a month to clear. Using MRDT, a false positivity rate of 5.9% had been reported in Burkina Faso among HIV-positive patients.

The 27.55% false negative results observed might be partly due to deletion or mutation of HRP2 gene in the malaria parasite, which is the most common target for MRDT. It has been reported to exhibit a high level of polymorphism. This is an important factor that may affect the performance of MRDT based on antigen detection. In addition, false negative results have been associated with blood samples taken beyond the period of malaria fever paroxysms. P. falciparum isolates without the HRP2 gene have been shown to be important contributors to false negative HRP2-based MRDT testing. Moreover, only Plasmodium falciparum releases HRP2; therefore, the presence of non-falciparum infection as another malaria species co-infection in Plasmodium falciparum may also give a false negative result. Other factors that might possibly affect MRDT field performance are shelf life and heat stability. In this study, the test kits were stored based on manufacturers’ recommendations and used before the expiry date on the MRDT kits.

Unexpectedly, with the MRDT, we observed a lower sensitivity of 34% among HIV-positive participants with a malaria density count between 500 cells/µL and 999 cells/µL compared to a 73% sensitivity when the malaria density count was less than 500 cells/µL. However, the specificity at between 500 cells/µL and 999 cells/µL was 97.5%. This was contrary to a previous study in Lagos, Nigeria, that observed an increase in sensitivity from 90.9% at parasite densities greater than 200 cells/µL to 97.6% at densities greater than 500 cells/µL. Generally, at lower parasitaemia, variability in sensitivity is more common. Similar observation of false negative MRDT results at parasite counts even higher than 1000 cells/µL have been reported in other studies and may be attributed to prozone effect observed with immunochromatographic tests such as MRDT. All the same, many MRDTs today can achieve excellent sensitivity and specificity for P. falciparum at parasite density lower than 500 cells/µL.

Besides this study, and to the best of our knowledge, only one other study has assessed performance of MRDT among HIV-positive patients based on febrile status in Africa. MRDT performance in our study showed similar sensitivity and specificity as reported by Mills et al., in febrile or non-febrile
cases in rural Uganda. Apparently, MRDT reliability is independent of febrile status.

MRDT performance was similar in terms of sensitivity, specificity and positive predictive value regardless of whether a participant was on co-trimoxazole prophylaxis or not. Information on similar studies is not available; however, with microscopy a relatively higher prevalence has been reported on those without co-trimoxazole prophylaxis compared with those on it.19,22,43

MRDT performance revealed a higher sensitivity among participants with a CD4+ T cell count greater than 500 cells/µL compared to a lower sensitivity among participants with a CD4+ T cell count under 500 cells/µL. Although information on similar studies is not available, it has been reported in a similar setting that HIV-positive participants with CD4+ T cell counts 250 cells/µL or higher are significantly less likely to have patent parasitaemia.10

The MRDT revealed a higher sensitivity among HIV-positive participants who were non-ART compared to those on ART. Lower incidence of malaria among HIV-positive adults on ART have been reported in different settings10,43,44 as well as reports of antimalarial properties of some antiretroviral drugs.45,46

Based on other reports in the general population, the use of MRDT method as an alternative to BSM in malaria endemic areas is recommended for epidemiological studies. However, the performance varied depending on species of the malaria parasite, level of parasitaemia, and immunity.47 For some of these reasons, such recommendation must be taken with caution in HIV-malaria co-infected persons, even though no differential effect of HIV infection on MRDT performance (specifically the SD Bioline antigen-based method) has been reported in literature.25

Strengths and limitations
This study was sufficiently powered having a large sample size of 1521 HIV-positive participants across the two health facilities. Apparently, this may be the first study to assess the performance of MRDT in an African setting of significantly high HIV and malaria co-morbidity in association with variables like immune status, parasitaemia and some clinical (co-trimoxazole prophylaxis, fever and ART status) factors.

The cross-sectional design of this study was a limitation as it was difficult to determine how the potential antimalarial effect of co-trimoxazole prophylaxis and ART could have affected MRDT performance over time. Note that we observed better diagnostic accuracy of MRDT among participants who were neither on co-trimoxazole prophylaxis nor on ART. Secondly, we did not measure individual body temperature to correlate it with participants’ reports of fever.

Conclusion
As observed in this study, the sensitivity of SD Bioline, which is based on P. falciparum histidine-rich protein type-2 and Plasmodium lactate dehydrogenase, is lower than WHO recommendation for MRDT.48 Thus, further evaluation is required to determine its suitability in malaria diagnosis among HIV-malaria co-infected patients in these settings.

It is worth speculating that a similar observation with the MRDT could have been observed in non–HIV-positive persons.

Trustworthiness, Reliability and Validity
The data reported in this current article reflect findings of work done on evaluation of standard diagnostic Bioline rapid test kits for malaria diagnosis among HIV patients in Kano, Nigeria, by our research team members who all participated in the study design, execution, collection, analysis of data and report writing.

The research outcomes presented in this report were from the diagnostic evaluation of standard diagnostic Bioline rapid test kits for malaria diagnosis among HIV-positive participants in Kano, Nigeria, at Infectious Diseases Hospital and Murtala Mohammed Specialist Hospital Kano. Although previous studies have reported on the evaluation of rapid malaria diagnosis against gold standard microscopy methods with a focus on the general population, it is worth noting that data among HIV-positive persons under different conditions are not readily available. Hence, this study sought to address paucity of data on performance evaluation of standard diagnostic Bioline among HIV-positive patients in relation to various factors such as fever status, CD4+ cell count, ART status, co-trimoxazole prophylaxis and malaria density.

The outcomes of this study and proposed recommendations could be useful in public health programme planning in such settings where HIV and malaria burden is high. Apart from disease prevalence data reported, malaria density count and performance of rapid test kits was also evaluated in addition to other clinical and useful variables. This may serve as a baseline upon which comparison may be made in future.

Acknowledgements
The authors wish to express their sincere appreciation to all the health care workers of both facilities especially the laboratory staffs for various support provided during the study and ensuring a conducive working atmosphere for success.

Competing interests
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article and its content is solely the authors’ responsibility and views expressed do not necessarily represent the official views of the study facilities and any affiliated institution listed.
Sources of support
None.

Authors’ contributions
H.A.M and T.I.O were the project leaders. F.E.J, T.I.O and S.A.A were responsible for the experimental and project design. F.E.J and S.A.A performed most of the experiments. H.A.M, F.E.J and T.I.O made conceptual contributions. F.E.J and S.A.A performed some of the experiments. F.E.J and T.I.O prepared the samples and data analysis. Data interpretation was performed by S.A.A, F.E.J, H.A.M and T.I.O. F.E.J and S.A.A drafted the manuscript. H.A.M and T.I.O reviewed the manuscript for scientific soundness. All authors reviewed and approved the final version of the manuscript.

References
1. United States Agency for International Development. President’s Malaria Initiative: Malaria operational plan FY 2013 [homepage on the Internet]. President’s Malaria Initiative; 2013. p. 1-74. Available from: https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy-13/fy-2013-malaria-program-plans/fy2013.pdf?

2. World Health Organization. World malaria report 2017 [homepage on the Internet]. 2017. Available from: http://apps.who.int/iris/bitstream/handle/10665/259402/9789241565513-eng.pdf;jsessionid=1

3. Dawaki S, Al-Mekhlafi HM, Ithoi I, et al. Is Nigeria winning the battle against malaria? Prevalence, risk factors and KAP assessment among Hausa communities in Kano State. Malar J [serial online]. 2016;15:351. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/27392040

4. AVERT.org. HIV and AIDS in Nigeria [homepage on the Internet]. 2017. Available from: https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/nigeria

5. Cunningham A, Riley EM. HIV and malaria co-infection. Immunity to parasitic infection. p. 335-352. Hoboken, NJ: John Wiley & Sons. https://doi.org/10.1002/9781118839321.ch19

6. Abu-Raddad LJ, Pattnak P, Kulin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science [serial online]. 2006;314(5805):1603–1606. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/17158321

7. Cohen C, Karstaedt A, Freau J, et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin Infect Dis [serial online]. 2005;41(11):1631–1637. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/16267737?article=pii:S0003053605009929. Full text

8. World Health Organization. Guidelines for the treatment of malaria [homepage on the Internet]. 2nd ed. WHO; 2010, 197 p. Available from: https://www.who.int/publications/2010/9789241547925_eng.pdf

9. Batwala V, Magnusson P, Nuwa F. Comparative feasibility of implementing rapid diagnostic test and microscopy for parasitological diagnosis of malaria in Uganda. Malar J [serial online]. 2011;10:373. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3571878&tool=pmcentrez&rendertype=abstract

10. Mills LA, Kagaya J, Nakagami G, et al. Performance of two malaria rapid diagnostic tests in febrile adult patients with and without human immunodeficiency virus-1 infection in Blantyre, Malawi. Am J Trop Med Hyg. 2010;82(6):199–202. Available from: https://doi.org/10.4269/ajtmh.2010.09-0408

11. Lee N, Gaaton ML, Pelenazo A, et al. Identification of optimal epitopes for Plasmodium falciparum rapid diagnostic tests that target histidine-rich proteins 2 and 3. J Clin Microbiol. 2012;50(4):1397–1405. https://doi.org/10.1128/JCM.00533-11

12. Baker J, McCarthy J, Gaaton M, et al. Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PFHRP2) and its effect on the performance of PFHRP2-based rapid diagnostic tests. J Infect Dis [serial online]. 2005;192:870–877. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3913328&tool=pmcentrez&rendertype=abstract

13. Wurtz N, Fall B, Bui K, et al. PFHRP2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal. Impact on rapid malaria diagnostic tests. Malar J [serial online]. 2013;12:34. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3571787&tool=pmcentrez&rendertype=abstract

14. Kumar OM, Oskoh S, Fontenille D, et al. Prevalence of Pfhrp2 and Pfhrp3 gene deletions in Puerto Lempira, Honduras. Malar J [serial online]. 2015;14:19. Available from: http://www.malarialjournal.com/content/14/1/19

15. Turner PR, vaccine, et al. Genetic variation in histidine rich proteins among Indian Plasmodium falciparum population: Possible cause of variable sensitivity of malaria rapid diagnostic tests. Malar J 2012;11:298. https://doi.org/10.1186/1475-2875-11-298

16. Tseroni M, Pervanidou D, Terkezou P, et al. Field application of SD bioline malaria Ag Pf/pan rapid diagnostic test for malaria in Greece. PLoS One. 2015;10(3):1–11. https://doi.org/10.1371/journal.pone.0120367

17. Koita OA, Dounkbo DK, Ouattara A, et al. False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. Am J Trop Med Hyg. 2012;86(2):194–198. Available from: https://doi.org/10.4269/ajtmh.2012.06065

18. Kozycki CT, Umulisa N, Rulisa S, et al. False-negative malaria rapid diagnostic tests in Rwanda: Impact of Plasmodium falciparum isolates lacking hsp22 and declining malaria transmission. Malar J. 2017;16:123. Available from: https://doi.org/10.1186/s12936-017-1768-1

19. Tinto H, Sembé O, Valea I, et al. Field evaluation of Plasmodium falciparum histidine-rich protein 2 (Hrp2) and Histidine-Rich Protein 3 (Pfrp3) Genes in Colombian Parasites. PLoS One [serial online]. 2015;10(7):e0131576. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/26615448?article=pii

20. Murillo Solano C, Akiniy Okoth S, Abdalla J, et al. Deletion of Plasmodium falciparum Histidine-Rich Protein 2 (pfhrp2) and Histidine-Rich Protein 3 (pfhrp3) Genes in Colombian Parasites. PLoS One [serial online]. 2015;10(3):1–11. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/26511448?article=pii

21. Andreoli A, Giorgetti PF, Pietra V, et al. Evaluation of a PfHRP-2 based rapid diagnostic test during an integrated community case management trial. Infect Dis Ther 2012, p. 335–352. Hoboken, NJ: John Wiley & Sons. https://doi.org/10.1002/1475-2875.12699

22. Jegede FE, Oyeyi TI, Abdulrahman SA, et al. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti- retroviral treatment (ART) clinics. Pak J Biol Sci. 2011;14(17):1637–1641. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/22550113

23. The World Health Organization. World malaria report 2017 [serial online]. 2017. Available from: http://www.who.int/malaria/publications/world-malaria-report-2017/

24. Tiono AB, Diarra A, Sanon S, et al. Low specificity of a malaria rapid diagnostic test (RDT) in a rural area of Guinea-Bissau. Am J Trop Med Hyg. 2009;80(6):1209–1215. Available from: https://doi.org/10.4269/ajtmh.2009.6.1209

25. Chinkhumba J, Nyanda M, Skarbinski J, et al. Performance of two malaria rapid diagnostic tests in febrile adult patients with and without human immunodeficiency virus-1 infection in Blantyre, Malawi. Am J Trop Med Hyg. 2008;79(2):199–202. Available from: https://doi.org/10.4269/ajtmh.2008.07-030

26. Jegede FE, Oyeyi TI, Abdulrahman SA, et al. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending antiretroviral treatment clinics. Pak J Biol Sci. 2011;14(17):1637–1641. Available from: http://www.ncbi.nlm.nih.gov/pmc/pmid/22550113
40. Bharti PK, Silawat N, Singh PP, et al. The usefulness of a new rapid diagnostic test, the First Response® Malaria Combo [pLDH/HRP2] card test, for malaria diagnosis in the forested belt of central India. Malar J [serial online]. 2008 [cited 2018 Jul 11];7:126. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2478667&tool=pmcentrez&rendertype=abstract

41. Mtové G, Nadim B, Amos B, et al. Use of an HRP2-based rapid diagnostic test to guide treatment of children admitted to hospital in a malaria-endemic area of north-east Tanzania. Trop Med Int Health. 2011;16(5):545–550. https://doi.org/10.1111/j.1365-3156.2011.02737.x

42. Gillet P, Mori M, Van Esbroeck M, et al. Assessment of the prozone effect in malaria rapid diagnostic tests. Malar J [serial online]. 2009;8:271. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2789093&tool=pmcentrez&rendertype=abstract

43. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007;21(15):2059–2066. https://doi.org/10.1097/QAD.0b013e3282ef6da1

44. Mishra LC, Bhattacharya A, Sharma M, et al. Short report: HIV protease inhibitors, indinavir or nevirapine, augment antimalarial action of artemisinin in vitro. Am J Trop Med Hyg. 2010;82(1):148–150. https://doi.org/10.4269/ajtmh.2010.09-0427

45. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother. 2006;50(2):639–648. https://doi.org/10.1128/AAC.50.2.639-648.2006

46. Parikh S, Gut J, Istvan E, et al. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother [serial online]. 2005;49(7):2983–2985. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15980379?tool=pmcentrez&rendertype=abstract

47. Kattenberg JH, Ochodo EA, Boer KR, et al. Systematic review and meta-analysis: Rapid diagnostic tests versus placental histology, microscopy and PCR for malaria in pregnant women. Malar J. 2011;10(1):321. https://doi.org/10.1186/1475-2875-10-321

48. World Health Organization. Making it work informal consultation on field trials and quality assurance on malaria rapid diagnostic tests regional office for the Western Pacific [homepage on the Internet]. Vol. 5. WHO; 2003. Available from: http://www.who.int/malaria/publications/atoz/rdt2.pdf